Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumours and Titrated in Combination Therapy With Temodar for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas.

Next Previous
Trial Profile

A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumours and Titrated in Combination Therapy With Temodar for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboxyamidotriazole orotate (Primary) ; Temozolomide
  • Indications Glioblastoma; Glioma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Tactical Therapeutics

Most Recent Events

  • 30 Apr 2025 Results assessing secondary outcome of overall survival (OS) and comparison with historical controls, presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 09 Jul 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2026.
  • 09 Jul 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top